Select acquires remainder of subsidiaries
By Melissa Trudinger
Tuesday, 30 November, 2004
Tuesday, 30 November, 2004
Select Vaccines (ASX: SLT) will acquire the remaining 35 per cent of its two subsidiaries Picoral and Hepgenics from the Burnet Institute.
The institute will be issued 4 million new shares plus 2 million options in Select Vaccines in return for its equity.
Ongoing R&D programs being conducted by the Burnet Institute for the two companies will continue to be funded through December 2005.
Related News
TGA approves donanemab for treatment of early Alzheimer's
The TGA has approved the first amyloid-targeting therapy for people with Alzheimer's in...
Ultra-processed foods linked to poor health, premature death
Evidence suggests a dose-response relationship between ultra-processed food consumption and...
Shorter radiotherapy course proves safe for prostate cancer
A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...
